Skip to content

US · BCRX · BIOTECHNOLOGY

BioCryst Pharmaceuticals, Inc. (BCRX) intrinsic value and stock valuation

$7.22as of 2026-11-21 · Mkt cap 2.31B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BioCryst Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values BCRX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from BCRX’s statements →

BioCryst Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Durham, NC 27703 biocryst.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$874.8M+117.9% 5y CAGRd
20112025
Net income
$263.9M
20112025
Free cash flow
$327.4M
20112025
Total equity
-$-119.15M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$874.8M$450.7M$331.4M$270.8M$157.2M
Operating income$341M-$-2.54M-$-103.71M-$-148.44M-$-177.72M
Net income$263.9M-$-88.88M-$-226.54M-$-247.12M-$-184.06M
EPSd$1.21M-$-430K-$-1.18M-$-1.33M-$-1.03M
Operating cash flow$329.9M-$-52.02M-$-95.14M-$-161.85M-$-142.16M
Capital expenditure-$-2.47M-$-1.12M-$-2.17M-$-1.35M-$-2.38M
Free cash flow$327.4M-$-53.14M-$-97.31M-$-163.2M-$-144.54M
Total assets$514.2M$490.4M$517M$550M$588.2M
Total debt$438.9M$841.4M$825.2M$741.5M$593.2M
Net debt$349.1M$736.5M$714.5M$436.7M$88.9M
Total equity-$-119.15M-$-475.93M-$-455.53M-$-294.6M-$-106.99M
Cash and short-term investments$274.8M$321.1M$389M$424.3M$507.6M
Income statement
20252024202320222021
Revenue$874.8M$450.7M$331.4M$270.8M$157.2M
Cost of revenue$19.1M$12.5M$4.66M$6.59M$7.26M
Gross profit$855.8M$438.2M$326.8M$264.2M$149.9M
Research and development expenses$166.1M$174.6M$216.6M$253.3M$208.8M
Selling, general and administrative expenses$348.7M$266.1M$213.9M$159.4M$118.8M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$514.8M$440.8M$430.5M$412.7M$327.6M
Cost and expenses$533.9M$453.3M$435.1M$419.3M$334.9M
Interest income$10.7M$14.8M$15.8M$5.13M$60K
Interest expense$78.9M$98.5M$108.2M$99.1M$59.3M
Depreciation and amortization$1.39M$1.25M$1.66M$1.44M$780K
Ebitda$347.7M$12.8M-$-116.33M-$-143.85M-$-121.74M
Operating income$341M-$-2.54M-$-103.71M-$-148.44M-$-177.72M
Total other income/expenses, net-$-73.6M-$-84.41M-$-122.52M-$-95.95M-$-4.09M
Income before tax$267.4M-$-86.95M-$-226.23M-$-244.38M-$-181.81M
Income tax expense$3.53M$1.93M$310K$2.73M$2.25M
Net income$263.9M-$-88.88M-$-226.54M-$-247.12M-$-184.06M
Weighted average shares outstanding$209.9M$206.7M$192.2M$185.9M$179.1M
Weighted average diluted shares outstanding$218.6M$206.7M$192.2M$185.9M$179.1M
Balance sheet
20252024202320222021
Cash and short-term investments$274.8M$321.1M$389M$424.3M$507.6M
Net receivables$106.8M$79.1M$57M$50.6M$29.4M
Inventory$5.4M$8.09M$28.7M$27.5M$15.8M
Total current assets$404.4M$422M$496M$516.5M$566.1M
Property, plant and equipment, net$19M$19.8M$20.9M$8.62M$15.2M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$61.2M$21.7M$0.00$18.1M$6.83M
Total non-current assets$109.8M$68.5M$21M$33.5M$22M
Total assets$514.2M$490.4M$517M$550M$588.2M
Accounts payable$15.8M$11.6M$20.9M$14.4M$27.8M
Short-term debt$1.63M$35.5M$2.65M$2.37M$1.82M
Deferred revenue$0.00$0.00$0.00$1.22M$1.42M
Total current liabilities$196.1M$160.4M$150M$105.5M$103.7M
Long-term debt$437.3M$806M$822.5M$739.1M$591.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$437.3M$806M$822.5M$739.1M$591.4M
Capital lease obligations$11.6M$10.1M$13.9M$8.17M$7.78M
Total liabilities$633.3M$966.4M$972.5M$844.6M$695.1M
Common stock$2.13M$2.08M$2.06M$1.88M$1.84M
Retained earnings-$-1.51B-$-1.77B-$-1.68B-$-1.45B-$-1.21B
Accumulated other comprehensive income (loss)$40K$920K$1.34M$30K$180K
Total equity-$-119.15M-$-475.93M-$-455.53M-$-294.6M-$-106.99M
Total investments$246.2M$237.9M$278.3M$137.6M$10M
Total debt$438.9M$841.4M$825.2M$741.5M$593.2M
Net debt$349.1M$736.5M$714.5M$436.7M$88.9M
Cash flow statement
20252024202320222021
Net income$263.9M-$-88.88M-$-226.54M-$-247.12M-$-184.06M
Depreciation and amortization$1.39M$1.25M$1.66M$1.44M$780K
Stock-based compensation$85.1M$65.4M$55.6M$44.7M$34.6M
Change in working capital-$-56.9M-$-87.28M-$-32.4M-$-58.95M$8.12M
Accounts receivable-$-36.81M-$-22.7M-$-6.09M-$-21.47M-$-20.82M
Inventory-$-1.64M-$-4.16M-$-1.45M-$-12.42M-$-8.77M
Accounts payable$57.8M-$-62.38M-$-16.81M-$-22.36M$39.4M
Net cash provided by operating activities$329.9M-$-52.02M-$-95.14M-$-161.85M-$-142.16M
Investments in property, plant and equipment-$-2.47M-$-1.12M-$-2.17M-$-1.35M-$-2.38M
Acquisitions, net-$-6.18M$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-13.69M$52.6M-$-131.5M-$-128.24M$15.8M
Common stock issued$9.17M$30K$340K$190K$50.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-332.44M-$-5.76M$32.5M$88M$359.7M
Net change in cash-$-103.32M-$-6.12M-$-193.79M-$-201.5M$233.4M
Cash at end of period$1.6M$106.3M$112.5M$306.2M$507.7M
Operating cash flow$329.9M-$-52.02M-$-95.14M-$-161.85M-$-142.16M
Capital expenditure-$-2.47M-$-1.12M-$-2.17M-$-1.35M-$-2.38M
Free cash flow$327.4M-$-53.14M-$-97.31M-$-163.2M-$-144.54M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BioCryst Pharmaceuticals, Inc.

        BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.

        CEO
        Charles K. Gayer
        Employees
        435
        Beta
        0.54

        Explore

        Frequently asked questions

        What is the intrinsic value of BioCryst Pharmaceuticals, Inc. (BCRX)?

        BioCryst Pharmaceuticals, Inc. (BCRX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BCRX undervalued?

        BCRX trades at a price of $7.22 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.